TY - JOUR T1 - Identification of the Human Liver Cytochrome P450 Enzymes Involved in the <em>In Vitro</em> Metabolism of a Novel 5-Lipoxygenase Inhibitor JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 970 LP - 976 VL - 26 IS - 10 AU - Joseph M. Machinist AU - Michael D. Mayer AU - Ellen M. Roberts AU - Bruce W. Surber AU - A. David Rodrigues Y1 - 1998/10/01 UR - http://dmd.aspetjournals.org/content/26/10/970.abstract N2 - In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) forms involved in the oxidative metabolism of [14C]ABT-761 and itsN-dehydroxylated metabolite, [14C]ABT-438, by human liver microsomes. The two compounds were metabolized by parallel pathways, to form the corresponding methylene bridge hydroxy metabolites. There was no evidence of sulfoxidation and/or ring hydroxylation. Over the ABT-761 and ABT-438 concentration ranges studied (1–300 μM), the rate of NADPH-dependent hydroxylation was linear with respect to substrate concentration ([S]) and did not conform to saturable Michaelis-Menten kinetics. Under these conditions ([S] &lt;KM ), the intrinsic clearance (Vmax/KM ) of ABT-438 was 10-fold higher than that of ABT-761 (1.7 ± 0.8vs. 0.17 ± 0.06 μl/min/mg, mean ± SD,N = 3 livers). The hydroxylation of both compounds was shown to be highly correlated (r = 0.83,p &lt; 0.01, N = 11 different human livers) with CYP3A-selective erythromycin N-demethylase activity, and the correlation between ABT-761 hydroxylation and tolbutamide hydroxylase (CYP2C9-selective) activity (r= 0.63, p &lt; 0.05, N = 10) was also statistically significant. Ketoconazole (2.0 μM), a CYP3A-selective inhibitor, inhibited the hydroxylation of both compounds by 53–67%, and sulfaphenazole (CYP2C9-selective) decreased activity by 10–20%. By comparison, α-naphthoflavone, a known activator of CYP3A, stimulated the hydroxylation of ABT-761 (8-fold) and ABT-438 (4-fold). In addition, the abundance-normalized rates of cDNA-expressed CYP-dependent metabolism indicated that hydroxylation was largely mediated (66–86%) by CYP3A(4). Therefore, it is concluded that the hydroxylation of ABT-761 and ABT-438 (≤10 μM) is primarily mediated by CYP3A, although CYP2C9 may play an ancillary role. The American Society for Pharmacology and Experimental Therapeutics ER -